CD79A and autoimmune polyendocrinopathy: So, the inclusion in aPL screening of IgA-aB2GPI may further identify a group of patients with APS-associated clinical manifestations (mostly male), and also with the same risk as IgG-isotype aPL, otherwise missed and the antibodies IgA-aB2GPI may be considered as a laboratory criterion for the diagnosis of APS.